CVKD Stock Forecast & Price Target

Cadrenal Therapeutics Inc is advancing its late-stage drug candidate, tecarfarin, which addresses significant unmet needs in anticoagulation therapy for patients with conditions requiring chronic anticoagulation. The company's collaboration with Abbott, a leader in the LVAD market, strengthens the outlook for tecarfarin's development, particularly for patients using the HeartMate 3 LVAD, indicating promising prospects backed by Abbott's extensive expertise. While additional funding will be essential to initiate the Phase 3 trials projected for mid-2025, the long-term growth potential in this therapeutic area may enhance investor interest and confidence.

Cadrenal Therapeutics Inc faces significant risks due to the possibility of failed or inconclusive clinical trials, which could hinder the progress of its drug candidate tecarfarin. Additionally, the company's reliance on securing adequate funding for development poses a substantial challenge, as insufficient financing could stall research and lead to delays. Lastly, the potential occurrence of dilutive capital raises could negatively impact shareholder value and investor confidence in the company’s financial health.